KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Amortization of Deferred Charges: 2018-2020

Historic Amortization of Deferred Charges for Castle Biosciences (CSTL) over the last 2 years, with Dec 2020 value amounting to $173,000.

  • Castle Biosciences' Amortization of Deferred Charges fell 26.07% to $173,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $839,000, marking a year-over-year decrease of 56.42%. This contributed to the annual value of $839,000 for FY2020, which is 56.42% down from last year.
  • Castle Biosciences' Amortization of Deferred Charges amounted to $173,000 in Q4 2020, which was down 19.16% from $214,000 recorded in Q3 2020.
  • Castle Biosciences' 5-year Amortization of Deferred Charges high stood at $916,000 for Q2 2019, and its period low was $139,273 during Q3 2018.
  • Over the past 3 years, Castle Biosciences' median Amortization of Deferred Charges value was $226,000 (recorded in 2020), while the average stood at $304,320.
  • In the last 5 years, Castle Biosciences' Amortization of Deferred Charges spiked by 216.64% in 2019 and then tumbled by 75.11% in 2020.
  • Castle Biosciences' Amortization of Deferred Charges (Quarterly) stood at $139,929 in 2018, then skyrocketed by 67.23% to $234,000 in 2019, then decreased by 26.07% to $173,000 in 2020.
  • Its last three reported values are $173,000 in Q4 2020, $214,000 for Q3 2020, and $228,000 during Q2 2020.